Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis
- 1 June 2015
- journal article
- case report
- Published by Elsevier BV in Journal of the Neurological Sciences
- Vol. 353 (1-2), 155-157
- https://doi.org/10.1016/j.jns.2015.04.010
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?Zeitschrift für Neurologie, 2014
- Progressive multifocal leukoencephalopathy after natalizumab discontinuationAnnals of Neurology, 2013
- The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathyMultiple Sclerosis Journal, 2013
- Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic ReviewPLOS ONE, 2013
- Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patientsJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findingsMultiple Sclerosis Journal, 2012
- Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseasesArthritis Care & Research, 2011
- Immune reconstitution inflammatory syndrome in natalizumab-associated PMLNeurology, 2011
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009